Browse Newsroom

Appointment of Henrik Bruun Andersen as Chief Financial Officer

January 30, 2023

PRESS RELEASE - Oslo, Norway - InsuLife, a Norwegian-based company dedicated to revolutionizing the insulin market by developing a transdermal spray, today announces that it has appointed Henrik Bruun Andersen as Chief Financial Officer.

Henrik has broad experience from the life sciences industry, having worked in the field for nearly 20 years. He started out as a Financial Director at MSD Norge and has since then held the role of Finance Director at OptiNose, Lundbeck and GSK Norge. Most recently, Henrik was Head of Supply Chain for Norway, Denmark and Iceland at Viatris.

Henrik has a Bachelor's in Business Administration and Economics and a Master's in Business Economics and Auditing from Copenhagen Business School. He also has a Master's in Accounting and Auditing from the Norwegian School of Economics.

“We are excited to welcome Henrik Bruun Andersen to InsuLife as Chief Financial Officer. He brings significant experience to the company, both as a seasoned financial professional and with highly relevant industry know-how. He is joining the company at an exciting time as we look to further develop our transdermal insulin spray,” commented Åge Nærdal, Chief Executive Officer, InsuLife.

Henrik Bruun Andersen, InsuLife’s new Chief Financial Officer, added: “Transdermal technology is an exciting and promising research field that has the potential to change how we administrate lifesaving medicine, such as insulin. I look forward to working closely with Åge and the broader team and to continue the development of the company’s technology.”


Åge Nærdal, Chief Executive Officer

About InsuLife

InsuLife is a pioneering private company based in Norway. InsuLife is dedicated to transforming the way in which insulin is administrated by diabetes patients by developing its unique transdermal spray, INS-2301 (formerly named Levellor™). A transdermal insulin spray has the potential to replace needle-based administration of insulin for diabetes patients looking for alternative administration methods. Today, 537 million people live with diabetes worldwide and research is estimating that more than 750 million people with be living with diabetes in 2045. 

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved